[go: up one dir, main page]

CL2017000563A1 - Uso de elsiglutida para tratar mucositis gastrointestinal que incluye diarrea inducida por quimioterapia. - Google Patents

Uso de elsiglutida para tratar mucositis gastrointestinal que incluye diarrea inducida por quimioterapia.

Info

Publication number
CL2017000563A1
CL2017000563A1 CL2017000563A CL2017000563A CL2017000563A1 CL 2017000563 A1 CL2017000563 A1 CL 2017000563A1 CL 2017000563 A CL2017000563 A CL 2017000563A CL 2017000563 A CL2017000563 A CL 2017000563A CL 2017000563 A1 CL2017000563 A1 CL 2017000563A1
Authority
CL
Chile
Prior art keywords
elsiglutide
induced diarrhea
treat gastrointestinal
gastrointestinal mucositis
includes chemotherapy
Prior art date
Application number
CL2017000563A
Other languages
English (en)
Inventor
Ruben Giorgino
Simona Roncoroni
Selma Calcagnile
Fabio Trento
Riccardo Spezia
Cecilia Moresino
Carsten Boye Knudsen
Original Assignee
Helsinn Healthcare Sa
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helsinn Healthcare Sa, Zealand Pharma As filed Critical Helsinn Healthcare Sa
Publication of CL2017000563A1 publication Critical patent/CL2017000563A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

<p>LA INVENCIÓN SE RELACIONA AL USO DE ELSIGLUTIDA PARA PREVENIR O REDUCIR LA OCURRENCIA DE DAÑO GASTROINTESTINAL CAUSADO POR AGENTES QUIMIOTERAPÉUTICOS, INCLUYENDO MUCOSITIS GASTROINTESTINAL Y DIARREA INDUCIDA POR QUIMIOTERAPIA (CID).</p>
CL2017000563A 2014-09-10 2017-03-08 Uso de elsiglutida para tratar mucositis gastrointestinal que incluye diarrea inducida por quimioterapia. CL2017000563A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462048520P 2014-09-10 2014-09-10

Publications (1)

Publication Number Publication Date
CL2017000563A1 true CL2017000563A1 (es) 2017-09-29

Family

ID=54548212

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000563A CL2017000563A1 (es) 2014-09-10 2017-03-08 Uso de elsiglutida para tratar mucositis gastrointestinal que incluye diarrea inducida por quimioterapia.

Country Status (18)

Country Link
US (1) US20160067311A1 (es)
EP (1) EP3191115A1 (es)
JP (1) JP2017532308A (es)
KR (1) KR20170052661A (es)
CN (1) CN107073081A (es)
AR (1) AR103119A1 (es)
AU (1) AU2015313919A1 (es)
BR (1) BR112017004577A2 (es)
CA (1) CA2959110A1 (es)
CL (1) CL2017000563A1 (es)
EA (1) EA201790552A1 (es)
IL (1) IL250928A0 (es)
MA (1) MA40623A (es)
MX (1) MX2017003166A (es)
PH (1) PH12017500426A1 (es)
SG (1) SG11201701690WA (es)
TW (1) TW201613634A (es)
WO (1) WO2016038455A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170087216A1 (en) * 2015-09-17 2017-03-30 Helsinn Healthcare Sa Therapeutic Uses of Elsiglutide
US11389424B2 (en) 2017-03-09 2022-07-19 Napo Pharmaceuticals, Inc. Methods and compositions for treating chemotherapy-induced diarrhea
EP3881861B1 (en) * 2017-06-16 2024-07-31 Zealand Pharma A/S Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
MX2022016367A (es) * 2020-06-19 2023-01-30 Napo Pharmaceuticals Inc Metodos y composiciones para el tratamiento de la diarrea inducida por quimioterapia.
CN115054683B (zh) * 2022-05-19 2023-06-09 唐颢 胰高血糖素样肽-2在制备缓解阿霉素心脏毒性药物中的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101163483A (zh) * 2005-04-22 2008-04-16 诺瓦西股份有限公司 使用活性维生素d化合物或其模拟物治疗、预防和缓解与化疗和放疗有关的肺部疾患
AU2006242998B2 (en) * 2005-05-04 2012-03-22 Zealand Pharma A/S Glucagon-like-peptide-2 (GLP-2) analogues
EP2314616A1 (en) * 2009-10-23 2011-04-27 Ferring B.V. Peptidic GLP-2 agonists

Also Published As

Publication number Publication date
EP3191115A1 (en) 2017-07-19
MA40623A (fr) 2016-03-17
AU2015313919A1 (en) 2017-03-16
JP2017532308A (ja) 2017-11-02
KR20170052661A (ko) 2017-05-12
TW201613634A (en) 2016-04-16
EA201790552A1 (ru) 2017-08-31
CA2959110A1 (en) 2016-03-17
PH12017500426A1 (en) 2017-07-31
CN107073081A (zh) 2017-08-18
MX2017003166A (es) 2017-06-19
BR112017004577A2 (pt) 2018-01-23
US20160067311A1 (en) 2016-03-10
SG11201701690WA (en) 2017-04-27
IL250928A0 (en) 2017-04-30
AR103119A1 (es) 2017-04-19
WO2016038455A1 (en) 2016-03-17

Similar Documents

Publication Publication Date Title
CU20190006A7 (es) Composiciones para inhibir masp-3
CL2018001790A1 (es) Procesos para preparar un inhibidor de jak1 y nuevas formas de este (divisional solicitud 201602748)
UY37381A (es) Compuestos que inhiben proteasas 3c y 3cl y métodos de uso de los mismos
CO2018013557A2 (es) Composiciones que comprenden cepas bacterianas
CL2017003142A1 (es) Composiciones que comprenden cepas bacterianas
CL2017000590A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
EA201691916A1 (ru) Биарильные ингибиторы киназы
CL2017001393S1 (es) Automovil
CL2017001185S1 (es) Automovil
UY37036A (es) Compuestos inhibidores de la quinasa de unión a tank
BR112019012343A2 (pt) anticorpos il-11ra
MX2017007049A (es) Anticuerpos anti-cd79b y métodos de uso.
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
MX381160B (es) Agonistas del receptor de apelina y metodos de uso.
EA201790649A1 (ru) Бензилзамещенные индазолы в качестве ингибиторов bub 1
TR201810635T4 (tr) Anti-jagged1 antikorları ve kullanım yöntemleri.
CL2017000792A1 (es) Derivados del ácido borónico
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
CL2017000563A1 (es) Uso de elsiglutida para tratar mucositis gastrointestinal que incluye diarrea inducida por quimioterapia.
DOP2016000073A (es) Composiciones y métodos para inhibir la expresión del gen alas1
MX2019010643A (es) Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2).
UY37472A (es) Sulfonilamidas sustituidas para combatir parásitos animales
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
UY37153A (es) Sulfonilamidas sustituidas para combatir parásitos animales
CL2015002113A1 (es) Compuestos de azetidinloxifenilpirrolidina